Strs Ohio acquired a new position in shares of CareDx Inc (NASDAQ:CDNA) during the 2nd quarter, HoldingsChannel reports. The firm acquired 9,500 shares of the company’s stock, valued at approximately $116,000.
Other large investors have also recently bought and sold shares of the company. Fox Run Management L.L.C. acquired a new position in CareDx during the 2nd quarter worth $178,000. Citadel Advisors LLC acquired a new position in CareDx during the 1st quarter worth $152,000. A.R.T. Advisors LLC acquired a new position in CareDx during the 1st quarter worth $185,000. Rhumbline Advisers acquired a new position in CareDx during the 2nd quarter worth $377,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new position in CareDx during the 2nd quarter worth $479,000. 72.84% of the stock is currently owned by hedge funds and other institutional investors.
CDNA has been the topic of several research reports. HC Wainwright set a $17.00 price objective on CareDx and gave the stock a “hold” rating in a report on Friday, August 10th. Piper Jaffray Companies upped their price objective on CareDx to $42.00 in a report on Wednesday, September 5th. Zacks Investment Research raised CareDx from a “sell” rating to a “hold” rating in a report on Monday, August 27th. BidaskClub cut shares of CareDx from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 23rd. Finally, TheStreet cut shares of CareDx from a “c-” rating to a “d” rating in a research report on Monday, June 11th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the stock. CareDx currently has a consensus rating of “Buy” and an average target price of $17.90.
In other CareDx news, COO Mitchell J. Nelles sold 39,649 shares of the company’s stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $12.48, for a total transaction of $494,819.52. Following the completion of the sale, the chief operating officer now owns 89,639 shares in the company, valued at approximately $1,118,694.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Sasha King sold 9,458 shares of the company’s stock in a transaction on Wednesday, August 1st. The shares were sold at an average price of $14.03, for a total transaction of $132,695.74. Following the sale, the insider now owns 71,792 shares of the company’s stock, valued at approximately $1,007,241.76. The disclosure for this sale can be found here. Insiders have sold a total of 92,962 shares of company stock valued at $1,594,372 in the last quarter. Corporate insiders own 3.40% of the company’s stock.
Shares of CareDx stock opened at $26.16 on Friday. CareDx Inc has a 52 week low of $2.70 and a 52 week high of $27.55. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.83 and a current ratio of 2.16.
CareDx (NASDAQ:CDNA) last issued its earnings results on Thursday, August 9th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03. The company had revenue of $17.82 million during the quarter, compared to analysts’ expectations of $15.30 million. CareDx had a negative net margin of 121.92% and a negative return on equity of 108.99%. research analysts expect that CareDx Inc will post -0.94 EPS for the current year.
CareDx, Inc, a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics.
Featured Article: Diversification in Your Portfolio
Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx Inc (NASDAQ:CDNA).
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.